Breakthrough cancer pain (BTcP): A synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy

Advances in Therapy

Volumn 31, Issue 7, 2014, Pages 657-682

  Zucco, Furio ^a   Bonezzi, Cesare ^b   Fornasari, Diego ^c  

^a Presenza Amica Association   (Italy)

^b IRCCS   (Italy)

^c CNR   (Italy)

Author keywords

Breakthrough cancer pain (BTcP); Cancer; Fentanyl; Pain; Pain exacerbation; Palliative care

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; BREAKTHROUGH PAIN; CAREGIVER; COMPLICATION; DRUG ADMINISTRATION ROUTE; FAMILY; HUMAN; NEOPLASM; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PATIENT CARE; TIME;

ANALGESICS, OPIOID; BREAKTHROUGH PAIN; CAREGIVERS; DRUG ADMINISTRATION ROUTES; FAMILY; FENTANYL; HUMANS; NEOPLASMS; PAIN MANAGEMENT; PAIN MEASUREMENT; PATIENT CARE TEAM; TIME FACTORS;

EID: 84905909175     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0130-z     Document Type: Review

References (58)

1. Hagen NA, Biondo P, Stiles C. Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research. Curr Pain Headache Rep. 2008;12:241-8.
2. Davies A, Dickman A, Reid C, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-8.
3. Corli C, Pizzuto M, OICP Research Group. Per qualche dolore in meno... Capire e trattare il breakthrough cancer pain. Roma: CIC Edizioni Internazionali; 2011.
4. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-81. (Pubitemid 20187930)
5. Agency for Healthcare Research and Quality. Management of cancer pain summary. 2001; evidence report/technology assessment number 35, AHRQ publication number 01-E033.
6. Walsh D. Pharmacological management of cancer pain. Semin Oncol. 2000;27:45-63. (Pubitemid 30108689)
7. Walsh D, Rivera NI, Davis MP, et al. Strategies for pain management: Cleveland Clinic Foundation guidelines for opioid dosing for cancer pain. Support Cancer Ther. 2004;1:157-64.
8. Zeppetella G. Opioids and breakthrough pain. In: Fifth Bristol Opioid conference. Bristol University Press; 2010.
9. Gomez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manag. 2002;24:45-52.
10. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55-64. (Pubitemid 36044654)
11. Caraceni A, Martini C, Zecca E, et al. Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-83. (Pubitemid 38771657)
12. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and nonmalignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206. (Pubitemid 40311842)
13. Zeppetella G. Breakthrough pain in cancer patients. Clin Oncol (R Coll Radiol). 2011;23:393-8.
14. Dickenson A. The neurobiology of chronic pain states. Anaesth Intensive Care Med. 2013;14:484-7.
15. Wordliczek J, Zajaczkowska R. Mechanisms in cancer pain. In: Hanna M, Zylicz Z, editors. Cancer pain. London: Springer; 2013.
16. Cervero F, Meyer RA, Campbell JN. A psychophysical study of secondary hyperalgesia: evidence for increased pain to input from nociceptors. Pain. 1994;58:21-8. (Pubitemid 24221815)
17. Caraceni A, Bertetto O, Labianca R, et al. Breakthrough/Episodic Pain Italian Study Group. Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI-Italian questionnaire for intense episodic pain. J Pain Symptom Manag. 2012;43:833-41.
18. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-15.
19. Campisi G, Paderni C, Saccone R, et al. Human buccal mucosa as an innovative site of drug delivery. Curr Pharm Des. 2010;16:641-52.
20. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011;3(Suppl 2):18-22.
21. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998;1:15-30.
22. Madhav NV, Shakya AK, Shakya P, Singh K. Orotransmucosal drug delivery systems: a review. J Control Release. 2009;140:2-11.
23. Bartlett JA, van der Voort Maarschalk K. Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech. 2012;13:1110-5.
24. Davis MP, Glare PA, Hardy J, Quigley C, editors. Opioids in cancer pain. 2nd ed. Oxford: Oxford University Press; 2009.
25. Smith HS. Considerations in selecting rapid-onset opioids for the management of breakthrough pain. J Pain Res. 2013;6:189-200.
26. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-6. (Pubitemid 28204805)
27. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-11. (Pubitemid 44627444)
28. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308-14.
29. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-85.
30. Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012;28:859-70.
31. Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177-91.
32. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617-24.
33. Moore N, Darwish M, Amores X, Schneid H. A review of the pharmacokinetic profile of transmucosal fentanyl formulations. Curr Med Res Opin. 2012;28:1781-90.
34. Darwish M, Kirby M, Robertson P Jr, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet. 2006;45:843-50. (Pubitemid 44182277)
35. Darwish M, Kirby M, Jiang JG, et al. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin Drug Investig. 2008;28:1-7. (Pubitemid 350274395)
36. Woodcock J, Khan M, Yu LX. Withdrawal of generic budeprion for nonbioequivalence. N Engl J Med. 2012;367:2463-5.
37. Bredenberg S, Duberg M, Lennernäs B, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003;20:327-34. (Pubitemid 37338538)
38. Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and noninvasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012;134:366-79.
39. Caraceni A, Hanks G, Kaasa S, European Association for Palliative Care (EAPC), et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68.
40. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer. 2007;96:1828-33. (Pubitemid 46912022)
41. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manag. 2004;27:352-9. (Pubitemid 38410903)
42. Pain therapy: Fans in Italy are 4 times more expensive than opioids. Available from: http://www.fondazioneisal.it/en/pubblicazioni/weblog/178-cura- del-dolore-in-italia-la-spesa-per-i-fans-e-4-volte-quella-per-gli-oppiacei.html. Accessed February 25, 2014.
43. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181-90.
44. Italian Law n. 38 of 2010. Available from: http://www.salute.gov.it/imgs/ C-17-pubblicazioni-1487-allegato.pdf. Accessed February 25, 2014.
45. Palliative Care and Pain Therapy - Reports to Italian Parliament. Available from: http://www.salute.gov.it/portale/temi/p2-6.jsp?lingua= italiano&id=3761&area=curePalliativeTerapiaDolore&menu=legge. Accessed February 25, 2014.
46. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults. NICE Clinical Guidelines, No. 140. National Collaborating Centre for Cancer (UK). Cardiff (UK): National Collaborating Centre for Cancer (UK); 2012 May.
47. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037-45.
48. Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224-31.
49. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-79.
50. Zeppetella G. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care (Engl). 2009;18:331-7.
51. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123-30. (Pubitemid 32274181)
52. Bornemann-Cimenti H, Wejbora M, Szilagyi IS, Sandner-Kiesling A. Fentanyl for the treatment of tumor-related breakthrough pain. Dtsch Arztebl Int. 2013;110:271-7.
53. Davies A, Zeppetella G, Andersen S, et al. Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756-63.
54. England R, Manderson C, Zadora-Chrzastowska S, et al. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care. 2011;1:349-51.
55. Mercadante S, Ferrera P, Adile C, Casuccio A. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manag. 2011;42:464-9.
56. Zucco F. Gli Hospice in Italia 2010: seconda rilevazione ufficiale. Bologna: ed. Bononia University Press, Settembre 2010, pp 1-420.
57. Fanelli C, Ventriglia G (eds). Il dolore cronico in medicina generale. Ministero della Salute 2010.
58. Le 10 Raccomandazioni. Decreto Direttore Generale Sanità, Regione Lombardia, n. 23454, 30/12/2004 con Oggetto: Determinazioni per la costituzione del Comitato Ospedale Senza Dolore (COSD) presso le Strutture Sanitarie di ricovero e cura e adozione del "Manuale Applicativo per la realizzazione dell'Ospedale senza Dolore". pag. 22. Available from: http://www.fedcp.org/ pdf/ospedale-senza-dolore.pdf. Accessed February 25, 2014.